Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

ClinicalTrials.gov ID: NCT02213913

Public ClinicalTrials.gov record NCT02213913. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Study identification

NCT ID: NCT02213913
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: University of Chicago; Other
Enrollment: 55 participants

Conditions and interventions

Conditions

Interventions

cyclophosphamide Drug
doxorubicin hydrochloride Drug
etoposide Drug
laboratory biomarker analysis Other
lenalidomide Drug
prednisone Drug
quality-of-life assessment Other
rituximab Biological
vincristine sulfate Drug

Drug · Other · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 28, 2014
Primary completion: Sep 30, 2024
Completion: Oct 28, 2024
Last update posted: Mar 10, 2026

2014 – 2024

United States locations

U.S. sites: 6
U.S. states: 2
U.S. cities: 5

Facility	City	State	ZIP	Site status
Rush University Medical Center	Chicago	Illinois	60612	—
University of Chicago	Chicago	Illinois	60637	—
Decatur Memorial Hospital Cancer Care Institute	Decatur	Illinois	62526	—
NorthShore University HealthSystem	Evanston	Illinois	60201	—
Illinois Cancer Care	Peoria	Illinois	61615	—
University of Maryland	Baltimore	Maryland	21202	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02213913, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 10, 2026 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02213913 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →